Unknown PHASE4 INTERVENTIONAL 2-arm NCT03132259

Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach

Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach

Sponsor: Mahidol University

Conditions Pituitary Tumor

Interventions high dose dexmedethomidine low dose dexmedethomidine

Updated 6 times since 2017 Last updated: May 25, 2017 Started: May 31, 2016 Primary completion: May 31, 2017 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Pituitary Tumor, this trial is ongoing. The trial is conducted by Mahidol University and has accumulated 6 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2019 — Jan 2021 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jun 2018 — Jun 2019 [monthly]

Recruiting PHASE4

▶ Show 1 earlier version

Jun 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mahidol University

Data source: Mahidol University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bangkok, Thailand